Literature DB >> 34801322

Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients.

Matteo Renzulli1, Elton Dajti2, Anna Maria Ierardi3, Nicolò Brandi4, Annalisa Berzigotti5, Matteo Milandri4, Benedetta Rossini2, Alfredo Clemente6, Federico Ravaioli2, Giovanni Marasco2, Francesco Azzaroli2, Gianpaolo Carrafiello3, Davide Festi2, Antonio Colecchia7, Rita Golfieri4.   

Abstract

PURPOSE: The aim of the present study was to propose and validate a standardized CT protocol for evaluating all the types of portosystemic collaterals (P-SC), including gastroesophageal varices and spontaneous portosystemic shunts (SPSS), and to evaluate the prognostic role of portal hypertension CT features for the prediction of the hepatic decompensation risk in cirrhotic patients.
METHODS: A retrospective cohort study of 184 advanced chronic liver disease who underwent CT scan between January 2014 and December 2017. Patients with an interval > 6 months between the imaging, elastometric, endoscopic and biochemical evaluation were excluded, as well as patients with previous transjugular intrahepatic portosystemic shunt (TIPS), liver transplantation (LT) or terminal medical conditions. Data on liver disease history, co-morbidities, endoscopic and radiologic findings were collected. The incidence of hepatic decompensation and other events, such as portal vein thrombosis, HCC, TIPS placement, LT, death, and its cause, were also recorded. The procedure was performed at baseline and after the administration of contrast agent using a multiphasic technique and bolus tracking. Two senior radiologists working in different centres and a non-expert radiologist reviewed all CT examinations, to evaluate both intra-observer and inter-observer variability of the CT protocol and to obtain an external validation. The radiological variables were evaluated using both univariate and adjusted multivariate competing risk regression models.
RESULTS: Both intra-observer and inter-observer agreement were excellent in detection and measurement of almost all types of P-SC. The presence of SPSS, a spleen diameter > 16 cm, a portal vein diameter > 17 mm and the presence of ascites resulted independent predictors of decompensation-free survival for cirrhotic patients and were incorporated in an easy-to-use score (AUROC = 0.799, p-value = 0.732) which can the risk of decompensation at 5 years, ranking it as low (11.3%), moderate (35.6%) or high (70.8%).
CONCLUSIONS: The CT protocol commonly performed during the HCC surveillance program for cirrhotic patients is valid for detecting all types of P-SC. The radiological score identified to predict the decompensation-free survival for cirrhotic patients could be an easy-to-use clinical tool.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Esophageal and gastric varices; Hepatic failure; Portal hypertension; Radiologic technology; Radiology

Mesh:

Year:  2021        PMID: 34801322     DOI: 10.1016/j.ejrad.2021.110010

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  3 in total

1.  Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers.

Authors:  Matteo Renzulli; Nicolò Brandi; Anna Pecorelli; Luigi Vincenzo Pastore; Alessandro Granito; Giuseppe Martinese; Francesco Tovoli; Mario Simonetti; Elton Dajti; Antonio Colecchia; Rita Golfieri
Journal:  Diagnostics (Basel)       Date:  2022-03-29

Review 2.  Computed Tomography Images of Spontaneous Portosystemic Shunt in Liver Cirrhosis.

Authors:  Fangfang Yi; Xiaozhong Guo; Qing-Lei Zeng; Benqiang Yang; Yanglan He; Shanshan Yuan; Ankur Arora; Xingshun Qi
Journal:  Can J Gastroenterol Hepatol       Date:  2022-06-08

3.  The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool?

Authors:  Matteo Renzulli; Anna Pecorelli; Nicolò Brandi; Stefano Brocchi; Francesco Tovoli; Alessandro Granito; Gianpaolo Carrafiello; Anna Maria Ierardi; Rita Golfieri
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.